Waregem (Belgium) / Rotterdam (Netherlands)*, April 7, 2010 – Arseus discloses the information with respect to the acquisition of treasury shares required under the new Article 207 of the Royal Decree of January 30, 2001 implementing the Belgian Company Code.
Arseus today announces that on March 31, it acquired 5,025 treasury shares on NYSE Euronext Brussels. Additionally, on March 30, 158 more shares were bought back on NYSE Euronext Brussels than stated in the press release of March 30, 2010.
Acquisition date
Number of shares
Average
price
Lowest
price
Highest
price
Amount
30 March 2010
158
€ 9.1289
€ 9.11
€ 9.24
€ 1,442
31 March 2010
5,025
€ 9.1197
€ 9.05
€ 9.20
€ 45,826
The Extraordinary Shareholders’ Meeting held on June 16, 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.
For more information:
Constantijn van Rietschoten, Investor Relations Manager
+31 88 33 11 222 (Office)
+31 6 536 91 585 (Mobile)
constantijn.van.rietschoten@arseus.com
Arseus profile
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the European healthcare sector. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical IT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
* This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: